Ocean Dx reported a clinical evaluation in which its rapid sepsis assay matched the gold‑standard reference, returning 100% sensitivity and 100% specificity against blood cultures while identifying infections in five hours. The test detects more than 1,000 bacterial species directly from whole blood and tripled the number of infections identified in the study. Investigators highlighted the assay’s potential to shorten time to pathogen identification and guide earlier, targeted antimicrobial therapy — a core objective in sepsis management and antibiotic stewardship. The developers noted the test’s clinical evaluation was preliminary and further multicenter validation is needed to confirm performance across broader patient populations. If validated, the platform could materially change sepsis workflows by reducing empirical broad‑spectrum antibiotic use, enabling pathogen‑directed therapy sooner and potentially improving outcomes and resource utilization in acute care settings.